In the world of genomic medicine, the CRISPR/Cas9 system is the ultimate "molecular scissor." However, even the sharpest tool is ineffective if it cannot reach its target. For researchers tackling complex diseases like lung tumors, the challenge has always been delivery.To address ...Learn More

In the rapidly shifting landscape of biotherapeutics, the traditional monoclonal antibody (mAb) is no longer the only protagonist. While mAbs have revolutionized the treatment of cancer and autoimmune diseases over the past few decades, the frontier of antibody engineering has ...Learn More

In the fast-evolving landscape of biopharmaceuticals, we are moving past the era of trial-and-error. If 2024 was the year Generative AI captured the public imagination, 2025-2026 is the era where AI delivers on its promise in the wet lab. Nowhere is this more evident than in ...Learn More

Neurodegenerative diseases represent one of the most daunting and heartbreaking challenges in modern medicine. Conditions like Alzheimer’s and Parkinson’s slowly rob individuals of their memories, motor functions, and independence. For decades, traditional pharmacological ...Learn More

For decades, Immunoglobulin G (IgG) has been the undisputed heavyweight champion of therapeutic antibodies. From treating chronic autoimmune diseases to revolutionizing oncology with immune checkpoint inhibitors, IgG molecules have dominated the biologics market. Their long serum ...Learn More